Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,250,725 papers from all fields of science
Search
Sign In
Create Free Account
bacteriolytic therapy
Therapy that uses anaerobic bacterium, particularly Clostridium novyi-NT, to kill cancer cells within the hypoxic regions of tumors.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Biological Response Modifier Therapy
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Learning from Clostridium novyi-NT: How to defeat cancer
Li Wang
,
Qing Wang
,
Xiaochao Tian
,
Xinli Shi
Journal of Cancer Research and Therapeutics
2018
Corpus ID: 4303539
Side effects associated with conventional anticancer therapies have prompted the new idea of solid tumor treatment strategy. One…
Expand
2007
2007
Targeting bacteriolytic therapy of solid tumors using salmonella typhimurium
N. Forbes
,
R. Arenas
,
S. Ganai
,
Brooke Bentley
2007
Corpus ID: 76082771
2007
2007
Targeting bacteriolytic therapy of solid tumors with attenuated Salmonella typhimurium
S. Ganai
2007
Corpus ID: 67991548
1992
1992
[Enzymes of a bacteriolytic lysoamidase preparation. Various properties of bacteriolytic protease L2].
O. A. Stepanaia
,
A. Severin
,
A. Kudriavtseva
,
V. I. Krupianko
,
A. Kozlovskii
,
I. Kulaev
Прикладная биохимия и микробиология
1992
Corpus ID: 45925289
Bacteriolytic proteinase L2 is able to cleave fluorogenic synthetic tripeptide anthranoyl-alanyl-alanyl-phenylalanyl-nitroanilide…
Expand
1979
1979
Effect of leukocyte hydrolases on bacteria
N. Ne'eman
,
M. Sela
,
+4 authors
I. Ginsburg
Inflammation
1979
Corpus ID: 22858103
Normal sera and plasma, derived from humans, calves, rats, rabbits, horses, human synovial fluids, inflammatory exudates, and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE